JPMorgan Chase & Co. Cuts BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Price Target to $23.00

Posted by Stanley Muller on Sep 14th, 2026

BridgeBio Oncology Therapeutics (NASDAQ:BBOT – Free Report) had its price target decreased by JPMorgan Chase & Co. from $25.00 to $23.00 in a research note released on Friday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Several other research firms have also recently weighed in on BBOT. Raymond James Financial cut their price objective on BridgeBio Oncology Therapeutics from $24.00 to $22.00 and set an “outperform” rating for the company in a research report on Wednesday. UBS Group downgraded shares of BridgeBio Oncology Therapeutics to an “overweight” rating in a report on Wednesday, July 8th. Leerink Partners cut their price objective on shares of BridgeBio Oncology Therapeutics to $27.00 and set an “outperform” rating for the company in a research report on Thursday. Wall Street Zen upgraded shares of BridgeBio Oncology Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 18th. Finally, Stifel Nicolaus decreased their target price on BridgeBio Oncology Therapeutics from $23.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $22.88.

Read Our Latest Report on BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics Stock Performance

BBOT stock opened at $4.95 on Friday. BridgeBio Oncology Therapeutics has a 1 year low of $4.90 and a 1 year high of $14.87. The company has a fifty day simple moving average of $8.66 and a 200 day simple moving average of $8.66. The firm has a market cap of $396.84 million, a PE ratio of -1.79 and a beta of 0.38.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($705.20) earnings per share (EPS) for the quarter. As a group, analysts forecast that BridgeBio Oncology Therapeutics will post -2.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Paradigm Biocapital Advisors LP boosted its holdings in BridgeBio Oncology Therapeutics by 21.2% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company’s stock valued at $28,317,000 after purchasing an additional 395,608 shares in the last quarter. Laurion Capital Management LP grew its stake in shares of BridgeBio Oncology Therapeutics by 40.1% in the 4th quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company’s stock valued at $18,341,000 after purchasing an additional 419,138 shares during the period. Armistice Capital LLC raised its holdings in shares of BridgeBio Oncology Therapeutics by 142.7% in the 4th quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock worth $12,520,000 after buying an additional 588,000 shares in the last quarter. Opaleye Management Inc. raised its holdings in shares of BridgeBio Oncology Therapeutics by 1,213.8% in the 2nd quarter. Opaleye Management Inc. now owns 700,000 shares of the company’s stock worth $5,334,000 after buying an additional 646,718 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of BridgeBio Oncology Therapeutics by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 561,987 shares of the company’s stock worth $7,039,000 after buying an additional 20,385 shares during the period. Institutional investors and hedge funds own 54.89% of the company’s stock.

About BridgeBio Oncology Therapeutics

(Get Free Report)

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.